Lipocine’s (LPCN) Hold Rating Reiterated at Canaccord Genuity

Lipocine (NASDAQ:LPCN)‘s stock had its “hold” rating reissued by research analysts at Canaccord Genuity in a research report issued on Tuesday. They currently have a $2.00 target price on the specialty pharmaceutical company’s stock. Canaccord Genuity’s price target would indicate a potential upside of 33.33% from the stock’s current price.

LPCN has been the topic of a number of other reports. HC Wainwright set a $3.00 price objective on Lipocine and gave the stock a “buy” rating in a research report on Friday, January 12th. Ladenburg Thalmann Financial Services reiterated a “buy” rating and issued a $11.00 price objective on shares of Lipocine in a research report on Thursday, January 11th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company’s stock. Lipocine presently has an average rating of “Hold” and a consensus price target of $13.50.

Shares of Lipocine (NASDAQ:LPCN) traded up $0.02 during mid-day trading on Tuesday, hitting $1.50. The stock had a trading volume of 57,786 shares, compared to its average volume of 890,898. Lipocine has a 12-month low of $1.15 and a 12-month high of $5.33.

Lipocine (NASDAQ:LPCN) last issued its quarterly earnings data on Monday, March 12th. The specialty pharmaceutical company reported ($0.25) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.21) by ($0.04). equities research analysts anticipate that Lipocine will post -0.85 earnings per share for the current year.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Goldman Sachs Group Inc. purchased a new position in shares of Lipocine in the 2nd quarter valued at approximately $300,000. Prosight Management LP purchased a new position in shares of Lipocine in the 4th quarter valued at approximately $1,283,000. Finally, Vanguard Group Inc. lifted its stake in shares of Lipocine by 39.7% in the 2nd quarter. Vanguard Group Inc. now owns 546,027 shares of the specialty pharmaceutical company’s stock valued at $2,195,000 after purchasing an additional 155,110 shares during the period. Institutional investors own 17.84% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece of content was originally posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this piece of content can be accessed at

Lipocine Company Profile

Lipocine Inc is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. Its primary development programs are based on oral delivery solutions for bioavailable drugs.

Receive News & Ratings for Lipocine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine and related companies with's FREE daily email newsletter.

Leave a Reply